Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment

• According to the American Cancer Society, cancer is the second leading cause of death globally.
• Oncology drugs are a cornerstone of modern cancer treatment.
• Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments.

Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced oncology drugs. Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are at the forefront of research and development, offering hope for millions of patients worldwide.

According to the American Cancer Society, cancer is the second leading cause of death globally, with 2,001,140 new cancer cases and 611,720 cancer deaths projected to occur in the United States in 2024 (https://ibn.fm/JA0DN). Approximately one in six deaths worldwide is due to cancer. The global cancer burden is expected to rise to 28.4 million cases by 2040, a 47% increase from 2020. This surge is driven by population growth, aging, and lifestyle factors such as tobacco use, poor diet, and physical inactivity.

Among the most prevalent and deadly forms of cancer are lung cancer, which is responsible for 1.8 million deaths annually, making it the leading cause of cancer-related mortality (https://ibn.fm/woQzB); colorectal cancer, which accounts for nearly 935,000 deaths each year (https://ibn.fm/ms7ty); breast cancer, the most commonly diagnosed cancer, with more than 2.3 million new cases annually (https://ibn.fm/O313h); and stomach and liver cancers, which account for approximately 968,784 (https://ibn.fm/zyWfM) and 866,136 deaths per year, respectively (https://ibn.fm/4EvTp).

These statistics highlight the enormous need for effective cancer treatments, especially for high-mortality cancers such as glioblastoma (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and certain types of lung cancer.

Oncology drugs are a cornerstone of modern cancer treatment. These drugs range from traditional chemotherapy to targeted therapies and immunotherapies, which aim to enhance the body’s immune response against cancer cells. Oncology drugs play a vital role in:

• Extending Survival: Many advanced therapies have significantly improved survival rates for cancers once considered untreatable.
• Improving Quality of Life: Targeted treatments and immunotherapies often come with fewer side effects than traditional chemotherapy, allowing patients to maintain a better quality of life.
• Personalized Medicine: Advances in genetic testing have enabled the development of personalized oncology drugs tailored to the unique genetic makeup of a patient’s tumor.

The global oncology drug market was valued at approximately $158 billion in 2022 and is projected to reach $327 billion by 2037, reflecting a compound annual growth rate (“CAGR”) of 7.5% (https://ibn.fm/xBVyH). However, despite these advances, significant gaps remain in treatment efficacy, accessibility, and affordability, underscoring the urgent need for continued innovation.

Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments. Their unique approach leverages antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. Calidi’s therapeutic strategy centers on harnessing the power of antitumor virotherapies, which are engineered to selectively infect and destroy cancer cells while sparing healthy tissue.

To enhance the delivery and efficacy of these viruses, Calidi uses extracellular enveloped viruses in its systemic platform and stem cells in its intratumoral platforms to protect the virotherapy from the body’s immune system during administration. The company’s dual approach offers multiple advantages, including targeted tumor destruction, in which viruses directly attack cancer cells, leading to their destruction; and immune system activation, a process that triggers a systemic immune response and trains the immune system to recognize and attack cancer cells throughout the body.

Calidi’s robust pipeline includes three key product candidates:

• RTNova (“CLD-400”): Targeting lung cancer and metastatic cancer, RTNova is a systemic platform that can be administered intravenously. The technology includes a vaccinia virus enveloped with a human cell membrane designed to protect the viral payload from the body’s immune system during administration and home in on cancer cells.
• SuperNova (“CLD-201”): Targeting solid tumors such as head and neck, triple-negative breast cancer and soft tissue sarcoma, SuperNova combines mesenchymal stem cells with vaccinia viruses. This therapy aims to overcome the limitations of traditional treatments by directly targeting tumors and activating the immune system.
• NeuroNova (“CLD-101”): This therapy is designed for patients with glioblastoma and other high-grade gliomas. It utilizes neural stem cells to deliver antitumor viruses directly to brain tumors, offering a promising new approach for one of the most aggressive and treatment-resistant cancers.

Calidi is also developing next-generation engineered antitumor viruses to broaden the scope of cancers treatable with its platform.

The groundbreaking work being done by Calidi Biotherapeutics has the potential to transform the oncology drug market and significantly improve cancer care. By focusing on high-need cancer types such as GBM, TNBC, sarcoma and lung cancer, Calidi addresses critical gaps in current treatment options. The company’s innovative therapies not only aim to improve survival rates but also reduce the debilitating side effects associated with many existing cancer treatments. As Calidi’s products advance through clinical trials, they hold the promise of offering new hope to patients facing some of the most challenging cancers.

The global burden of cancer continues to grow, making the need for effective oncology drugs more pressing than ever. As a leader in innovative cancer treatment, Calidi Biotherapeutics is poised to play a pivotal role in shaping the future of oncology drug development. Its pioneering therapies represent a new frontier in the fight against cancer, offering hope for improved outcomes and a better quality of life for millions of patients worldwide.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office